The shortage of ADHD medications has been a growing concern over the past year, with patients reporting difficulties accessing prescriptions and experiencing disruptions in treatment regimens. The FDA’s new plan is designed to address these challenges by boosting production limits and ensuring a more stable supply of the drugs.
The plan also includes improved monitoring of drug availability and more transparent reporting from drug manufacturers about production and distribution challenges.
Read more about the plan here.
At the Becker's Fall Behavioral Health Summit, taking place November 4–5 in Chicago, behavioral health leaders and executives will explore strategies for expanding access to care, integrating services, addressing workforce challenges and leveraging innovation to improve outcomes across the behavioral health continuum. Apply for complimentary registration now.
